Advertisement

Treatment of Ocular Manifestations of Behçet’s Disease

  • F. Davatchi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 528)

Keywords

Visual Acuity Cytotoxic Drug Disease Activity Index Anterior Uveitis Hemorrhagic Cystitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davatchi, F., Shahram, F., Akbarian, M., et al., 1997, Behçet’s disease — Analysis of 3443 cases. APLAR J. Rheumatol. 1: 2–5.Google Scholar
  2. 2.
    Davatchi, F., 1998, Behçet’s disease. In Textbook of Clinical Rheumatology (H.S. Howe, and P.H. Feng, eds.), National Arthritis Foundation, Singapore, pp. 298–315.Google Scholar
  3. 3.
    Davatchi, F., Shahram, F., Chams, H., et al., 2001, Long-term outcome of vision in Behçet’s disease. Arthritis Rheum. 44: S1309.Google Scholar
  4. 4.
    Davatchi, F., Shahram, F., Chams, H., et al., 2003, The influence of the delay of aggressive treatment on the vision and its outcome in Behçet’s disease. In Adamantiades-Behçet’s disease (Ch.C. Zouboulis, ed.), Kluwer/Plenum, London, pp. 493–494.Google Scholar
  5. 5.
    Davatchi, F., Shahram, F., Chams, H., et al., 1991, Pulse cyclophosphamide in ophthalmological manifestations of Behçet’s disease. In Behçet’ s Disease. Basic and Clinical Aspects (J.D. O’Duffy, and E. Kokmen, eds.), Marcel Decker, New York, pp. 555–561.Google Scholar
  6. 6.
    Davatchi, F., Shahram, F., Chams, H., et al., 1998, Pulse cyclophosphamide for ocular manifestations of Behçet’s disease. Cohort study on 283 patients. Rev. Rheum. (Engl. Ed.) 65: 692.Google Scholar
  7. 7.
    Shahram, F., Davatchi, F., Chams, H., et al., 1993, Low dose pulse cyclophosphamide LDP) in ophthalmologic lesions of Behçet’s disease. In Behçet’s Disease (B. Wechsler, and P. Godeau, eds.), Excerpta Medica, Amsterdam, pp. 683–686.Google Scholar
  8. 8.
    Shahram, F., Davatchi, F., Chams, H., et al., 1992, Pulse cyclophosphamide versus pulse methotrexate in ophthalmological manifestations of Behçet’s disease. In APLAR Rheumatology 1992 (A. Nasution, J. Darmawan, and H. Isbagio, eds.), Churchill Livingstone, Tokyo, pp. 119–122.Google Scholar
  9. 9.
    Shahram, F., Davatchi, F., Chams, H., et al., 1990, Methotrexate in ocular Behçet disease. Preliminary report. In First APLAR Symposium on the Therapy of Rheumatic Diseases, Seoul, Korea. Abstract FP-23.Google Scholar
  10. 10.
    Davatchi, F., Shahram, F., Chams, H., et al., 1998, Methotrexate for ocular lesions of Behçet’s disease. Cohort study on 262 patients. Arthritis Rheum. 41: S356.Google Scholar
  11. 11.
    Shahram, F., Davatchi, F., Chams, H., et al., 1993, Comparing 3 methods of cytotoxic therapy in ophthalmologic lesions of Behçet’s disease. In Behçet’s Disease (B. Wechsler, and P. Godeau, eds.), Excerpta Medica, Amsterdam, pp. 635–640.Google Scholar
  12. 12.
    Shahram, F., Davatchi, F., Chams, H., et al., 1997, Cyclosporin in sever ocular lesions of Behçet’s disease. In Behçet’s Disease (M. Hamza, ed.), Pub Adoua, Tunis, pp. 421–423.Google Scholar
  13. 13.
    Davatchi, F., Shahram, F., Chams, H., 2000, Azathioprine for the treatment of ophthalmological lesions of Behçet’s disease. In Behcet’s Disease (D. Bang, E.-S. Lee, S. Lee, eds.), Design Mecca Publishing, Seoul, pp. 898–900.Google Scholar
  14. 14.
    Shahram, F., Chams, H., Davatchi, F., et al., 2000, Combination therapy with low dose pulse cyclophosphamide and methotrexate in ocular lesions of Behçet’s disease. In Behcet’s Disease (D. Bang, E.-S. Lee, S. Lee, eds.), Design Mecca Publishing, Seoul, pp. 926.Google Scholar
  15. 15.
    Davatchi, F., Shahram, F., Gharibdoost F., et al., 1996, Outcome analysis of ocular lesions in Behçet’s disease with 6 different therapeutic methods. Arthritis Rheum. 39: S217.Google Scholar
  16. 16.
    Davatchi, F., 1997, Neuro-ophthalmic Behçet’s. In APLAR 3rd Symposium on the Therapy of Rheumatic Diseases (T.P. Torralba, C.M. Amante, and S.T.G. Victorio-Navarra, eds.), Excerpta Medica, Hong Kong, pp. 16–17.Google Scholar
  17. 17.
    Davatchi, F., 2000, Treatment of ocular manifestations of Behçet’s disease. In Proceedings of the 9th Asia Pacific League of Associations for Rheumatology Congress, Beijing, pp. 174–176.Google Scholar
  18. 18.
    Adler, Y.D., Krause, L., Foerster, M.H., et al., 2000, Treatment of ocular Adamantiades-Behçet’s disease with interferon-alpha. In Behcet’s Disease (D. Bang, E.-S. Lee, S. Lee, eds.), Design Mecca Publishing, Seoul, pp. 446–447.Google Scholar
  19. 19.
    Wechsler, B., Huong-Boutin, L.T.D., Amoura, Z., et al., 2000, Efficacy of alpha interferon in severe and refractory uveitis of Behçet’s disease. In Behcet’s Disease (D. Bang, E.-S. Lee, S. Lee, eds.), Design Mecca Publishing, Seoul, pp. 483–488.Google Scholar
  20. 20.
    Kötter, I., Stübiger, N., Eckstein, A.K., et al., 2000, Recmbinant human interferon-α2A (IFNα2A) in the treatment of ocular Behçet’s disease (BD). In Behcet’s Disease (D. Bang, E.-S. Lee, S. Lee, eds.), Design Mecca Publishing, Seoul, pp. 491–493.Google Scholar
  21. 21.
    Nussenblatt, R.B., Palestine, A.G., and Clan, C.C., 1985, Effectiveness of cyclosporin therapy for Behçet’s disease. Arthritis Rheum. 28: 671–679.PubMedGoogle Scholar
  22. 22.
    Whitcup, S.M., Salvo, E.C. Jr., and Nussenblatt. R.B., 1994, Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet’s disease. Am. J. Ophthalmol. 118: 39–45.PubMedGoogle Scholar
  23. 23.
    Davatchi, F., Shahram, F., Gharibdoost, F., et al., 1997, Outcome of patients with ocular lesions of Behçet’s disease non responding to classical treatments. Arthritis Rheum. 40: S66.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • F. Davatchi
    • 1
  1. 1.Behçet’s Disease Unit, Rheumatology Research CenterTehran University for Medical Sciences, Shariati HospitalTehranIran

Personalised recommendations